Free tool
FAERS Monitor: Iwilfin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215500 or its brand name (Iwilfin, Eflornithine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
42
Serious
31
74% of reports
Hospitalization
5
Death reported
13
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death7
- deafness6
- alopecia5
- condition aggravated5
- disease progression4
- neuroblastoma4
- disease recurrence2
- dry mouth2
- eyelash changes2
- joint dislocation2
- motor developmental delay2
- off label use2
- skin mass2
- accident1
- adverse drug reaction1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 18 |
| 2025 | 6 |
| 2026 | 6 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,117 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eyelash changes | 2 | 5729.0 | 1469.5 | 6,369 |
| neuroblastomaSignal | 4 | 5290.6 | 2071.7 | 16,027 |
| motor developmental delay | 2 | 1740.6 | 449.0 | 1,948 |
| skin mass | 2 | 150.0 | 38.8 | 166 |
| deafnessSignal | 6 | 114.9 | 54.8 | 569 |
| joint dislocation | 2 | 94.8 | 24.5 | 104 |
| accident | 1 | 41.9 | 6.0 | 10 |
| disease recurrence | 2 | 21.1 | 5.4 | 21 |
| disease progressionSignal | 4 | 16.9 | 6.7 | 45 |
| alopeciaSignal | 5 | 12.8 | 5.6 | 43 |
| dry mouth | 2 | 12.3 | 3.2 | 11 |
| condition aggravatedSignal | 5 | 8.2 | 3.6 | 25 |
| adverse drug reaction | 1 | 5.6 | 0.8 | 1 |
| deathSignal | 7 | 4.1 | 2.1 | 14 |
| off label use | 2 | 1.1 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.